Life Sciences Group,Inc
Life Science Pharmaceuticals (LSP) develops novel therapeutics to treat cancer, diabetes, and other serious illnesses, with a diverse portfolio of product candidates in pre-clinical and clinical development. The company fosters close relationships with academic institutions and collaborates with international pharmaceutical companies. LSP has licensing agreements with prestigious institutions and companies such as The Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, Dana Farber Cancer Center, MIT, and AbbVie. The company's mission is to develop drugs for unmet medical needs, particularly in oncology, leveraging innovative research and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Life Sciences Group,Inc
Products
Tumor-selective monoclonal antibody targeting an EGFR transitional epitope
A monoclonal antibody that selectively binds a tumor-exposed epitope of the epidermal growth factor receptor and has been characterized for tumor specificity, internalization and payload delivery potential.
Antibody-drug conjugate for EGFR-expressing tumors
An ADC constructed to remain stable in circulation and selectively release cytotoxic agent inside targeted tumor cells; investigated in glioblastoma and squamous cell tumor models and clinical studies.
ABT-806
A humanized monoclonal antibody that selectively targets the epidermal growth factor receptor (EGFR), currently in Phase 1 clinical trial for the treatment of advanced solid tumors expressing EGFR.
Monoclonal antibody 806 (mAb806)
Monoclonal antibody 806 targets a proprietary epitope on EGFR, binding to cancer cells but not normal tissue cells. It offers tumor-specific targeting and has been shown to reduce tumor growth in preclinical studies. It is licensed to Life Science Pharmaceuticals and further developed by Abbott Biotechnology.
LSP monoclonal antibody (806)
A monoclonal antibody targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
ABT-414/806
A monoclonal antibody (806) targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
Tumor-selective monoclonal antibody targeting an EGFR transitional epitope
A monoclonal antibody that selectively binds a tumor-exposed epitope of the epidermal growth factor receptor and has been characterized for tumor specificity, internalization and payload delivery potential.
Antibody-drug conjugate for EGFR-expressing tumors
An ADC constructed to remain stable in circulation and selectively release cytotoxic agent inside targeted tumor cells; investigated in glioblastoma and squamous cell tumor models and clinical studies.
ABT-806
A humanized monoclonal antibody that selectively targets the epidermal growth factor receptor (EGFR), currently in Phase 1 clinical trial for the treatment of advanced solid tumors expressing EGFR.
Monoclonal antibody 806 (mAb806)
Monoclonal antibody 806 targets a proprietary epitope on EGFR, binding to cancer cells but not normal tissue cells. It offers tumor-specific targeting and has been shown to reduce tumor growth in preclinical studies. It is licensed to Life Science Pharmaceuticals and further developed by Abbott Biotechnology.
LSP monoclonal antibody (806)
A monoclonal antibody targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
ABT-414/806
A monoclonal antibody (806) targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
Services
Negotiation, execution and management of licensing agreements and strategic collaborations between academic institutions and pharmaceutical partners for therapeutic candidates.
Negotiation, execution and management of licensing agreements and strategic collaborations between academic institutions and pharmaceutical partners for therapeutic candidates.
Expertise Areas
- Monoclonal antibody therapeutics
- Antibody-drug conjugate development
- Preclinical in vivo efficacy testing
- Early-phase clinical trial management
Key Technologies
- Monoclonal antibodies
- Antibody-drug conjugates (ADC)
- Epitope mapping
- Immunohistochemistry (IHC)
News & Updates
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).